CN116421255A - Upper digestive tract hemostasis device - Google Patents
Upper digestive tract hemostasis device Download PDFInfo
- Publication number
- CN116421255A CN116421255A CN202310701767.6A CN202310701767A CN116421255A CN 116421255 A CN116421255 A CN 116421255A CN 202310701767 A CN202310701767 A CN 202310701767A CN 116421255 A CN116421255 A CN 116421255A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- port
- upper gastrointestinal
- hemostatic
- feeding tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 28
- 230000023597 hemostasis Effects 0.000 title abstract description 24
- 239000000017 hydrogel Substances 0.000 claims abstract description 104
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 54
- 230000002496 gastric effect Effects 0.000 claims abstract description 45
- 230000000740 bleeding effect Effects 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 208000032843 Hemorrhage Diseases 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 10
- 230000029663 wound healing Effects 0.000 claims description 8
- 108010027529 Bio-glue Proteins 0.000 claims description 2
- 230000006835 compression Effects 0.000 abstract description 14
- 238000007906 compression Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002575 gastroscopy Methods 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 3
- 210000003462 vein Anatomy 0.000 description 11
- 206010046996 Varicose vein Diseases 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 8
- 208000027185 varicose disease Diseases 0.000 description 8
- 239000003364 biologic glue Substances 0.000 description 6
- 210000003928 nasal cavity Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 4
- 206010030172 Oesophageal haemorrhage Diseases 0.000 description 4
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 4
- 206010056091 Varices oesophageal Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000024170 esophageal varices Diseases 0.000 description 4
- 201000010120 esophageal varix Diseases 0.000 description 4
- 208000007232 portal hypertension Diseases 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000004283 incisor Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 206010065441 Venous haemorrhage Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002599 gastric fundus Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
- A61J15/0003—Nasal or oral feeding-tubes, e.g. tube entering body through nose or mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
- A61J15/0026—Parts, details or accessories for feeding-tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B2017/12004—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord for haemostasis, for prevention of bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides an upper gastrointestinal hemostatic device, and relates to the technical field of medical appliances, wherein the device comprises: the nasal feeding tube and the hydrogel fixed on the nasal feeding tube are used for stopping bleeding at the bleeding part of the upper digestive tract after the hydrogel swells with water. In the device, the characteristic that hydrogel swells when meeting water is utilized, so that the traditional nasal feeding tube has the effect of compression hemostasis on the upper digestive tract besides the function of fluid food, and a timely and effective upper digestive tract hemostasis medical device is provided for medical institutions without gastroscopy.
Description
Technical Field
The invention relates to the technical field of medical appliances, in particular to an upper gastrointestinal hemostatic device.
Background
The upper gastrointestinal hemorrhage is a common clinical disease, and in the related technology, the upper gastrointestinal hemorrhage is mainly treated by inserting a gastroscope electric coagulation hemostasis method, which can only be implemented in a hospital with excellent conditions, the upper gastrointestinal hemorrhage of a patient is difficult to control in the initial onset of the disease, and the treatment time is delayed when the patient arrives at the hospital for further treatment.
Therefore, how to stop bleeding in the upper digestive tract is a current urgent problem to be solved.
Disclosure of Invention
Aiming at the problems existing in the prior art, the embodiment of the invention provides an upper digestive tract hemostasis device.
The present invention provides an upper gastrointestinal hemostatic device comprising: the nasal feeding tube and the hydrogel fixed on the nasal feeding tube are used for stopping bleeding at the bleeding part of the upper digestive tract after the hydrogel swells with water.
Optionally, the device further comprises a syringe, a first port of the syringe is connected with the hydrogel, and a second port of the syringe is located outside the upper gastrointestinal hemostatic device.
Optionally, the second port is used for inputting a target object, and the first port is used for outputting the target object; the target comprises at least one of the following: water; hemostatic drugs; and a hydrogel dissolving agent for dissolving the hydrogel.
Optionally, the syringe further comprises a third port for delivering a wound healing drug to a bleeding site of the upper digestive tract.
Optionally, an injection path control device is arranged between the third port and the first port;
wherein, when the second port inputs the target object, the injection path control device controls the first port and the second port to form a passage;
the injection path control device controls the third port to form a passageway with the second port in the case where the second port is inputted with the wound healing drug.
Optionally, hemostatic drugs are prepared in the hydrogel.
Optionally, the hydrogel is located between 30 cm and 40 cm of the nasogastric tube.
Optionally, the hydrogel is located at the bottom of the nasal feeding tube, which acts on the upper gastrointestinal tract internal bleeding site.
Optionally, the hydrogel and the nasal feeding tube are fixed through biological glue.
According to the upper gastrointestinal hemostatic device provided by the invention, the characteristics that hydrogel swells when meeting water are utilized, so that the traditional nasal feeding tube has the function of fluid food, the treatment effect of performing compression hemostasis on the upper gastrointestinal tract is achieved, and the upper gastrointestinal hemostatic medical device is provided for medical institutions without gastroscopy.
Drawings
In order to more clearly illustrate the invention or the technical solutions of the prior art, the following description will briefly explain the drawings used in the embodiments or the description of the prior art, and it is obvious that the drawings in the following description are some embodiments of the invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic diagram of an upper gastrointestinal hemostatic device according to the present invention;
FIG. 2 is a schematic diagram of a second embodiment of an upper gastrointestinal hemostatic device according to the present invention;
FIG. 3 is a third schematic view of an upper gastrointestinal hemostatic device according to the present invention;
fig. 4 is a schematic diagram of an upper gastrointestinal hemostatic device according to the present invention.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings, and it is apparent that the described embodiments are some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
In order to facilitate a clearer understanding of the various embodiments of the present application, some relevant background knowledge is first presented below.
Esophageal bleeding can be caused by a number of factors, of which esophageal fundus varices (Esophagogastric Varices, EGV) are one cause of esophageal bleeding; EGV is a complication of portal hypertension (Portal Hypertension, PH) that can be life threatening to the patient.
It will be appreciated that there are subtle differences in treatment regimens due to anatomical location of the esophageal veins as opposed to the gastric veins. The anatomical principle of esophageal varices (Esophageal Varices, EV) is that blood of an esophageal submucosal venous plexus enters esophageal peripheral side branch veins which are distributed along the longitudinal rows of the esophagus through a penetrating branch vein, and the esophageal side branch veins of the cervical segment flow back into the hypothyroid vein, and the thoracic segment flow back into the odd vein, intercostal vein, bronchial vein and the like; the reflux of the abdominal segment into the left gastric vein and finally the reflux of the left gastric vein into the liver, PH eventually results in a blocked reflux of blood, which shunts from the portal circulation to these low pressure thin wall submucosal venous systems, causing varicose veins and elevated internal pressure and wall tension. Varices and elevated internal pressure and wall tension may lead to esophageal bleeding.
Transjugular intrahepatic portosystemic shunt (Transjugular Intrahepatic Portosystemic Shunt, TIPS) has been widely used in the related art to treat portal hypertension-related complications, thereby avoiding varicose veins and elevated internal pressure and wall tension.
However, patients are easy to have serious adverse events such as hepatic encephalopathy after operation, and the life quality and the survival time of the patients are seriously affected.
In addition, for liver dysfunction, severe jaundice (serum gall red > 8555 p.mol/L) is unsuitable for liver transplants, hepatic encephalopathy is above grade I, or cardiopulmonary dysfunction patients prohibit the use of TIPS for treating portal hypertension related complications.
Because these patients are prone to serious adverse events such as hepatic encephalopathy after using the operation, the life quality and the survival time of the patients are seriously affected. Therefore, the operation is limited, the number of endoscopists is small, and TIPS is difficult to popularize due to operation difficulty, conditions and the like.
Therefore, how to treat esophageal bleeding caused by varices and an increase in internal pressure and wall tension is a popular subject of current research.
The upper digestive tract hemostasis device provided by the invention can perform compression hemostasis on the upper digestive tract bleeding part under the assistance of hydrogel, and can particularly perform hemostasis on upper digestive tract varicose veins; in addition, the upper gastrointestinal hemostatic device provided by the invention has a simple structure, is more suitable for popularization to primary hospitals, and has a wide application prospect.
In summary, by utilizing the water swelling property of the hydrogel, the upper gastrointestinal hemostatic device provided by the invention has the effect of compression hemostasis on the upper gastrointestinal tract besides the function of liquid diet, and provides a timely and effective upper gastrointestinal hemostatic medical device for medical institutions without gastroscopy.
The upper gastrointestinal hemostatic device provided by the present invention will be described in detail with reference to fig. 1 to 3. Fig. 1 is a schematic structural view of an upper gastrointestinal hemostatic device provided by the invention, and the upper gastrointestinal hemostatic device in fig. 1 comprises a nasal feeding tube 101 and a hydrogel 102 fixed on the nasal feeding tube 101, wherein the hydrogel 102 is used for hemostasis of a bleeding part of an upper gastrointestinal tract after swelling with water.
In this embodiment, hydrogel 102 is a three-dimensional network polymer material that swells in water but does not dissolve in water. Functional hydrogels are of great interest in biomedical applications due to their excellent properties of natural extracellular matrix-like structures, adjustable mechanical properties, elastic network structures, wound exudate absorption, etc.
The hydrogel 102 has the effects of stopping bleeding, resisting bacteria and promoting healing, the invention provides a custom-made formed hydrogel patch with the length of about 10 cm to 15 cm on the basis of the structure of the nasal feeding tube 101, and a qualified operator can cut according to the actual condition of a patient and then adhere to the nasal feeding tube 101 to form a hydrogel wrapping layer; among them, the nasal feeding tube 101, also called a gastric tube, is a medical device that helps patients who cannot swallow to deliver necessary moisture and food.
After the hydrogel 102 is delivered to the bleeding site of the upper digestive tract, the hydrogel 102 swells with water to thereby compress and stop bleeding at the bleeding site.
According to the upper gastrointestinal hemostatic device provided by the invention, the characteristics that hydrogel swells when meeting water are utilized, so that the traditional nasal feeding tube has the function of fluid food, the treatment effect of performing compression hemostasis on the upper gastrointestinal tract is achieved, and the upper gastrointestinal hemostatic medical device is provided for medical institutions without gastroscopy.
Optionally, the hydrogel 102 has hemostatic drugs prepared therein.
Thus, the biocompatibility of the hydrogel 102, and in particular the environmental responsiveness it possesses, may be utilized to achieve osmotic administration to the upper gastrointestinal bleeding site. In practical applications, the drug should be a group of drugs, i.e. therapeutic drugs after acute hemorrhage, including antibiotics and rapid hemostatic drugs, such as somatostatin, vasopressin, etc.
The environmental responsiveness is mainly temperature sensitivity and PH responsiveness. The pH value of the lower region of the upper digestive tract is different from that of other regions, and the bleeding part is used as a lesion part and has a pH value difference with normal physiological tissues. Therefore, the pH value responsiveness of the hydrogel can be utilized to carry the hemostatic drug with a specific dosage form.
In the above embodiment, by preparing the hemostatic drug in the hydrogel 102, the effect of the drug hemostasis can be further achieved on the basis of the compression hemostasis.
Optionally, the hydrogel is located between 30 cm and 40 cm of the nasogastric tube.
In practice, the patient's esophagus is about 25 cm in length and about 40-42 cm in length from the central incisors to the distal esophagus.
The bleeding part of the varices of the esophagus of the patient is concentrated at 1/3 section below the esophagus, and the bleeding part takes the central incisors as the starting point, which is equivalent to the position of 30 cm to 40 cm of the nasal feeding tube. Thus, where the outer portion of the nasogastric tube is wrapped around a water-swellable hydrogel, the operator should cut the hydrogel to a suitable length according to the patient's actual condition and adhere to the corresponding anatomical location of the nasogastric tube.
In the above embodiment, the hydrogel is arranged at a position of 30 to 40 cm of the nasal feeding tube, so that hemostasis can be effectively performed on esophageal varices bleeding.
Alternatively, in another possible implementation, the hydrogel may be located at the bottom of a nasogastric tube that acts on the upper intragut hemorrhage site.
In this embodiment, hydrogel can be placed at the bottom of the nasal feeding tube, and the length of the nasal feeding tube can be used to perform compression hemostasis on various bleeding sites of the upper digestive tract. The upper digestive tract includes pharynx, esophagus, stomach, etc.
In practical application, the length of the nasal feeding tube entering the patient can be manually controlled according to the bleeding position of the upper digestive tract of the patient, for example, the bleeding position of the patient is positioned at 1/3 section below the esophagus, the nasal feeding tube can be stretched into the patient for 30 cm to 40 cm, and the hydrogel positioned at the bottom of the nasal feeding tube is used for compression hemostasis of the bleeding position; for another example, the bleeding part of the patient is positioned at the bottom of the gastric cavity, so that the nasal feeding tube can be fully extended into the patient, the hydrogel at the bottom of the nasal feeding tube can touch the bleeding part at the bottom of the gastric cavity, and compression hemostasis is realized on the bottom of the gastric cavity.
When the hydrogel is positioned at the bottom of the nasal feeding tube, the size of the hydrogel needs to be adaptively adjusted based on the size of the nasal cavity of the patient, so that the hydrogel can smoothly pass through the nasal cavity of the patient under the condition of not expanding when the hydrogel is in contact with water.
Optionally, the hydrogel 102 and the nasal feeding tube 101 are fixed by biological glue.
In this embodiment, the hydrogel 102 is formed into a sheet/strip shape, and the body of the hydrogel 102 has been loaded with a non-toxic and non-irritating bio-glue, which is similar to a double sided adhesive tape, and the operator can directly adhere to the anatomical location of the patient corresponding to the nasogastric tube 101 after removing the formed hydrogel 102 from the package, or can cut to a suitable length and adhere to the nasogastric tube 101.
It should be noted that the nontoxic biological glue can be degraded in human body. The biological glue may be, for example, "merro".
In another implementation, the hydrogel may be secured to the nasogastric tube directly using a degradable surgical suture.
Fig. 2 is a second schematic structural view of the upper gastrointestinal hemostatic device provided by the present invention, where the upper gastrointestinal hemostatic device in fig. 2 includes a nasal feeding tube 201, a hydrogel 202 fixed on the nasal feeding tube 201, and a syringe 203, and the hydrogel 202 is inflated with water to stop bleeding at a bleeding part of the upper gastrointestinal tract; a first port 2031 of the syringe 203 is connected to the hydrogel 202 and a second port 2032 of the syringe 203 is located outside the upper gastrointestinal hemostatic device.
Optionally, the second port 2032 is used for inputting a target object, and the first port 2031 is used for outputting the target object; the target comprises at least one of the following:
a) Water;
b) Hemostatic drugs;
c) A hydrogel dissolving agent for dissolving the hydrogel 202.
In this embodiment, in the case where water is included in the target object, water is inputted from the second port 2032 of the syringe 203 and outputted from the first port 2031 to the hydrogel 202.
Accordingly, hydrogel 202 has a coefficient of expansion. Hydrogel 202 rapidly absorbs a large number of water molecules when exposed to water, expanding many times as much as it was. After the operator inserts the upper gastrointestinal hemostatic device into the upper gastrointestinal tract of the patient through the nasal cavity, a certain amount of purified water is injected through the injection tube 203, so that the empty water gel 202 absorbs a large amount of water, and its own volume is amplified to many times of the original volume. The limited lumen space of the upper digestive tract is extruded by the hydrogel which absorbs water and expands, and the bleeding part of the upper digestive tract is mechanically pressed, so that the hemostatic effect is achieved.
In the case where a hemostatic drug is included in the target object, the hemostatic drug is input from the second port 2032 of the syringe 203 and output from the first port 2031 to the hydrogel 202.
By the method, the effect of stopping bleeding of the medicine can be further achieved on the basis of the compression hemostasis of the hydrogel.
Where a hydrogel dissolution agent is included in the target, the hydrogel 202 may be dissolved by the particular hydrogel dissolution agent.
In practice, after having achieved the purpose of hemostasis by compression, hydrogel 202 may be dissolved by a specific hydrogel dissolving agent. The dissolving agent is nontoxic and nonirritating to digestive tract, and acts on specific molecular structure of hydrogel to dissolve it and relieve compression state of upper digestive tract.
It will be appreciated that after the hydrogel 202 attached to the nasogastric tube 201 is dissolved by the dissolving agent, the nasogastric tube 201 can be removed from the patient.
Optionally, hemostatic drugs are prepared in the hydrogel 202.
That is, the hemostatic drug may be prepared in the hydrogel 202 in advance, or the hemostatic drug may be inputted from the second port 2032 of the syringe 203 and outputted from the first port 2031 to the hydrogel 202.
Optionally, the hydrogel 202 is located between 30 cm and 40 cm of the nasogastric tube 201.
By the method, hemostasis can be effectively performed on esophageal varices.
Optionally, the hydrogel 202 is fixed with the nasal feeding tube 201 by biological glue.
Fig. 3 is a third schematic structural view of the upper gastrointestinal hemostatic device provided by the invention, wherein the upper gastrointestinal hemostatic device in fig. 3 comprises a nasal feeding tube 301, a hydrogel 302 fixed on the nasal feeding tube 301, and a syringe 303, and the hydrogel 302 is inflated with water to stop bleeding at the upper gastrointestinal tract; a first port 3031 of the syringe 303 is connected to the hydrogel 302, and a second port 3032 of the syringe 303 is located outside the upper gastrointestinal hemostatic device; the third port 3033 of the syringe 303 is used to deliver wound healing medication to the bleeding site of the upper digestive tract.
In this embodiment, after hemostasis is performed on the bleeding part of the upper digestive tract, the wound healing drug may be input from the second port 3032 and output from the third port 3033, so that the wound healing drug may directly act on the bleeding part of the upper digestive tract to assist the bleeding part in accelerating healing.
Optionally, an injection path control device 304 is disposed between the third port 3033 and the first port 3031;
wherein, in the case where the second port 3032 inputs the target object, the injection path control device 304 controls the first port 3031 and the second port 3032 to form a passage;
in the case where the second port 3032 inputs the wound healing drug, the injection path control device 304 controls the third port 3033 to form a passage with the second port 3032.
Wherein the target comprises at least one of the following: a) Water; b) Hemostatic drugs; c) Hydrogel dissolving agent.
In practice, in the case where the bleeding condition of the upper digestive tract is improved, a hydrogel dissolving agent may be injected into the second port 3032 of the syringe 303 so that the first port 3031 delivers the hydrogel dissolving agent to the hydrogel 302, thereby dissolving the hydrogel 302 to release the compression. After dissolution, the nasogastric tube 301 can be withdrawn from the patient.
Optionally, hemostatic drugs are prepared in the hydrogel 302.
Optionally, the hydrogel is located between 30 cm and 40 cm of the nasogastric tube.
Optionally, the hydrogel is located at the bottom of the nasal feeding tube, which acts on the upper gastrointestinal tract internal bleeding site.
Optionally, the hydrogel and the nasal feeding tube are fixed through biological glue.
Fig. 4 is a schematic structural diagram of the upper gastrointestinal hemostatic device provided by the invention, wherein the upper gastrointestinal hemostatic device in fig. 4 comprises a nasal feeding tube 401, a hydrogel 402 and a syringe 403, wherein the hydrogel 402 is fixed at the bottom of the nasal feeding tube 401, and the hydrogel 402 is used for stopping bleeding at the bottom of a gastric cavity after being inflated with water; the first port 4031 of the syringe 403 is connected to the hydrogel 402 and the second port 4032 of the syringe 403 is located outside the upper gastrointestinal hemostatic device.
The upper gastrointestinal hemostatic device provided by the embodiment can utilize the hydrogel 402 to perform compression hemostasis on the gastric fundus venous hemorrhage.
When the hydrogel is positioned at the bottom of the nasal feeding tube, the size of the hydrogel needs to be adaptively adjusted based on the size of the nasal cavity of the patient, so that the hydrogel can smoothly pass through the nasal cavity of the patient under the condition of not expanding when the hydrogel is in contact with water.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (9)
1. An upper gastrointestinal hemostatic device, comprising: the nasal feeding tube and the hydrogel fixed on the nasal feeding tube are used for stopping bleeding at the bleeding part of the upper digestive tract after the hydrogel swells with water.
2. The upper gastrointestinal hemostatic device of claim 1, further comprising a syringe having a first port connected to the hydrogel and a second port located outside the upper gastrointestinal hemostatic device.
3. The upper gastrointestinal hemostatic device of claim 2, wherein the second port is for inputting a target and the first port is for outputting the target; the target comprises at least one of the following: water; hemostatic drugs; and a hydrogel dissolving agent for dissolving the hydrogel.
4. The upper gastrointestinal hemostatic device of claim 3, wherein the syringe further comprises a third port for delivering a wound healing drug to a bleeding site of the upper gastrointestinal tract.
5. The upper gastrointestinal hemostatic device of claim 4, wherein an injection path control device is disposed between the third port and the first port;
wherein, when the second port inputs the target object, the injection path control device controls the first port and the second port to form a passage;
the injection path control device controls the third port to form a passageway with the second port in the case where the second port is inputted with the wound healing drug.
6. An upper gastrointestinal hemostatic device according to any one of claims 1 to 3, wherein the hydrogel has hemostatic drugs prepared therein.
7. The upper gastrointestinal hemostatic device of any one of claims 1-3, wherein the hydrogel is located between 30 cm and 40 cm of the nasogastric tube.
8. A device according to any one of claims 1 to 3, wherein the hydrogel is located at the bottom of the nasogastric tube which acts on the site of hemorrhage in the upper digestive tract.
9. A device according to any one of claims 1 to 3, wherein the hydrogel is held between the nasal feeding tube by means of a bio-glue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310701767.6A CN116421255A (en) | 2023-06-14 | 2023-06-14 | Upper digestive tract hemostasis device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310701767.6A CN116421255A (en) | 2023-06-14 | 2023-06-14 | Upper digestive tract hemostasis device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421255A true CN116421255A (en) | 2023-07-14 |
Family
ID=87087675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310701767.6A Pending CN116421255A (en) | 2023-06-14 | 2023-06-14 | Upper digestive tract hemostasis device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421255A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201356594Y (en) * | 2009-03-05 | 2009-12-09 | 宣世英 | Novel upper digestive tract hemostat |
| CN108653797A (en) * | 2018-05-15 | 2018-10-16 | 钱兴 | A kind of nasal packing is with expanded tampon sponge and preparation method thereof |
| CN115737950A (en) * | 2022-12-09 | 2023-03-07 | 重钢总医院 | Multifunctional pleuroperitoneal cavity drainage tube |
| CN115869458A (en) * | 2022-12-26 | 2023-03-31 | 四川大学华西医院 | Composition for stopping bleeding and preparation method and application thereof |
-
2023
- 2023-06-14 CN CN202310701767.6A patent/CN116421255A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201356594Y (en) * | 2009-03-05 | 2009-12-09 | 宣世英 | Novel upper digestive tract hemostat |
| CN108653797A (en) * | 2018-05-15 | 2018-10-16 | 钱兴 | A kind of nasal packing is with expanded tampon sponge and preparation method thereof |
| CN115737950A (en) * | 2022-12-09 | 2023-03-07 | 重钢总医院 | Multifunctional pleuroperitoneal cavity drainage tube |
| CN115869458A (en) * | 2022-12-26 | 2023-03-31 | 四川大学华西医院 | Composition for stopping bleeding and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU84711U1 (en) | NOBILE CATHETER-DRAINAGE | |
| CN116421255A (en) | Upper digestive tract hemostasis device | |
| Adamantos et al. | Emergency care of the cat with multi‐trauma | |
| CWALİNSKİ et al. | Endoscopic vacuum assisted closure of gastrocutaneous fistula after sleeve gastrectomy combined with fibrin sealant | |
| US20220118237A1 (en) | Devices for topical delivery of active agents to a target site | |
| RU2625277C1 (en) | Method for chronic haemorrhoid low-invasive treatment | |
| RU156334U1 (en) | DEVICE FOR AUTOMATIC RETURN OF BILES TO THE DIGESTIVE TREATMENT IN PATIENTS WITH MECHANICAL JAUNDICE | |
| RU2797099C1 (en) | Method of local anesthesia of the median laparotomic wound using semi-permeable membranes. | |
| RU2534844C2 (en) | Method for preventing peritoneal adhesions following surgical operation | |
| RU2231303C1 (en) | Method for surgical treating the cyst of pancreatic caput at chronic complicated pancreatitis | |
| RU137670U1 (en) | DEVICE FOR RETURNING BILES TO THE DIGESTIVE TREATMENT IN PATIENTS WITH MECHANICAL JAUNDICE | |
| RU2736164C1 (en) | Method for preventing adhesion in abdominal cavity after laparoscopic surgical operation in experiment | |
| RU2344769C1 (en) | Method of rear colonic-gastric anastomosis application during esophagoplastics | |
| RU2514093C2 (en) | Device for injection therapy of gastroesophageal reflux disease | |
| RU2468758C2 (en) | Method of treating injury of lower third of esophagus, complicated with mediastinitis | |
| RU2283057C1 (en) | Method for carrying out temporary endoscopic obturation of gastric perforation | |
| Khakimov et al. | New Method of Endoscopic Hemostasis in Complicated Bleeding Gastroduodenal Ulcers | |
| RU2451490C1 (en) | Method of surgical management of anal fistulas with using bioplastic material | |
| RU2566213C1 (en) | Method for applying double spiral continuous haemostatic liver suture | |
| RU2169531C2 (en) | Method for carrying out chemical denervation of unpaired visceral branches of abdominal aorta | |
| Ajay Kumar | A Comparitive study between Patients of Small and Large Bowel Perforation managed by Stomas with Drains and Without Drains | |
| RU2380098C2 (en) | Method for prevention of postocclusive syndrome in x-ray endovascular treatment of myomas of body of uterus | |
| Tivers et al. | Gastric dilation–volvulus syndrome in dogs: 2. Surgical and postoperative management | |
| CIUNTU et al. | FROM CLASSIC TO MODERN PROCEDURES IN THE TREATMENT OF EARLY EXTERNAL HIGH-OUTPUT POSTOPERATIVE DIGESTIVE FISTULAS. | |
| UA151355U (en) | Bandage for the prevention of complications during the vacuum treatment of patients with peritonitis, with fistulas and wounds (options) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |